Pharmaceuticals, Biotechnology and Life Sciences
– Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million – GAAP Net Income of $75.0 Million for Fiscal Year 2020 – $140.3 Million in Cash and Investments and No Funded Debt – Company to Host Quarterly Conference Call at …
Daix (France), March 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccha…
Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim Cohort Enrolled Efficacy Data from Animal Studies of…
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 ch…